Skip to main content

Market Overview

Keke Palmer Criticizes 'Miracle' Weightloss Drug Ozempic Users: 'Folks With Diabetes Ain't Able To Get It'

Share:
Keke Palmer Criticizes 'Miracle' Weightloss Drug Ozempic Users: 'Folks With Diabetes Ain't Able To Get It'

Actress and singer Keke Palmer recently expressed her views on the ‘miracle’ weight loss drug Ozempic and her postpartum body on her podcast, “Baby, this is Keke Palmer,” ET Canada reports.

Critique of Ozempic: Palmer also criticized the Ozempic craze, a drug originally made for people with diabetes but now popular for weight loss.

“Ever since the girls have been using it to lose weight, the folks with diabetes ain’t able to get [it], the prices have gone up,” she lamented.

See Also: Ozempic Alternatives: These Two Drugs Show Promise In Affordability And Effectiveness For Weight Loss

Embracing Postpartum Body: Palmer, who recently became a mother, is ready to take on more action roles post-baby.

“So it’s interesting after the baby to see all the extra stuff I have to work with and how much my fear of having extra weight actually became a strength as it pertained to weight training and working out,” she said.

Palmer emphasizes that her fitness goals are a personal choice and not a societal expectation.

Read Next: Elon Musk, Mark Zuckerberg, Jeff Bezos Shine Spotlight On Body Image Issues, Ozempic Craze Intensifies

Image via Shutterstock


Engineered by Benzinga Neuro, Edited by
Pooja Rajkumari


The GPT-4 Benzinga Neuro content generation system exploits the extensive Benzinga Ecosystem, including native data, APIs, and more to create comprehensive and timely stories for you.
Learn more.


 

Related Articles

View Comments and Join the Discussion!

Posted-In: Diabetes Keke Palmer Ozempic weightlossNews Health Care Media General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com